Sonnet BioTherapeutics to Present at Biotech Conference
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a pioneering force in the field of immunotherapy, is gearing up to present at the prestigious MedInvest Biotech & Pharma Conference. The event will take place in Palo Alto, bringing together industry leaders and innovators in the biotechnology space. This conference represents a valuable opportunity for Sonnet to showcase its novel approach to combating cancer through innovative therapeutic drugs.
Leadership Insights and Presentation Details
Raghu Rao, the Interim Chief Executive Officer of Sonnet, will be taking the stage on September 25, sharing insights into the company's work in targeting the tumor microenvironment (TME). This presentation is set for 9:40 AM PT and will highlight Sonnet's commitment to developing cutting-edge treatments aimed at improving patient outcomes. Besides the presentation, the management team will be available for one-on-one meetings, providing an intimate setting for discussions with investors.
Engagement with the Investor Community
Sonnet recognizes the importance of building strong relationships with its investors and stakeholders. At the MedInvest Conference, the company's leadership is dedicated to engaging qualified members of the investor community. This initiative is part of Sonnet's broader strategy to keep stakeholders informed about the latest developments and advancements in their ongoing research.
Webcast and Conference Accessibility
For those unable to attend in person, Sonnet will offer a live webcast of the presentation. This accessibility ensures that anyone interested in the company’s advancements can easily tune in and stay up-to-date with Sonnet's developments. The webcast will be accessible via the Events page of the Investors section on Sonnet's official website.
Innovative Therapeutic Platform
At the heart of Sonnet's strategy lies its proprietary FHAB (Fully Human Albumin-Binding) platform. This unique technology enhances the delivery of biologic drugs, optimizing their therapeutic properties and safety. By utilizing a fully human single chain antibody fragment that binds to human serum albumin (HSA), Sonnet is positioned to effectively target tumor and lymphatic tissues.
Lead Programs Targeting Cancer
Sonnet's lead product candidate, SON-1010, or IL-12-FHAB, is currently under investigation for the treatment of solid tumors, specific sarcoma types, and ovarian cancer. This promising therapeutic agent is being evaluated in a Phase 1/2a clinical trial, in partnership with Roche, particularly focusing on platinum-resistant ovarian cancer. The collaboration illustrates Sonnet's commitment to leveraging top-tier partnerships to enhance the development of its therapies.
In addition to SON-1010, Sonnet is advancing a second therapeutic, SON-1210, which combines IL12-FHAB with IL15 for solid tumors. This initiative is partnered with the Sarcoma Oncology Center and is set to embark on a Phase 1/2a study for pancreatic cancer, demonstrating the company’s dedication to exploring various applications of its innovative platform.
Investor Relations Contact
Engagement with investors is crucial for Sonnet, and the company has made outreach easy and effective. For investor relations, interested parties can connect with the JTC Team, LLC, and reach out to Jenene Thomas at 908-824-0775 or via email at SONN@jtcir.com. Ensuring that investors have direct access to the company's representatives is a part of Sonnet's transparent communication strategy.
Frequently Asked Questions
What is Sonnet BioTherapeutics focused on?
Sonnet focuses on developing immunotherapeutic drugs that target the tumor microenvironment to improve cancer treatment outcomes.
When and where will Sonnet present its developments?
Sonnet will present at the MedInvest Biotech & Pharma Conference on September 25 in Palo Alto.
How can investors engage with Sonnet during the conference?
Investors can participate in one-on-one meetings with Sonnet's management team during the conference.
What technology does Sonnet BioTherapeutics utilize?
Sonnet employs the FHAB platform, which enhances the delivery and action of biologic drugs targeting cancer.
What are Sonnet's lead programs?
Sonnet’s lead programs include SON-1010 for platinum-resistant ovarian cancer and SON-1210 for pancreatic cancer.
